According to the Philippine Food and Drug Administration (FDA), the regulation of electronic cigarettes, e-cigarette devices, and other heated tobacco products (HTP) must be under the jurisdiction of the Philippines' FDA and cannot be transferred to the Department of Trade and Industry (DTI) as these products involve public health. This information was reported by vaporcoice and translated by 2FIRSTS.
According to PhilStar Global, the FDA has released a statement outlining its position to urge the President to veto the e-cigarette bills (Senate Bill No. 2239 and House Bill No. 9007) which would transfer regulatory authority of the products to the DTI.
The statement from the Philippine FDA reads, "The Department of Health, through the FDA, has taken on its constitutional mandate to protect the right to health of every Filipino by establishing an effective regulatory system.
Contrary to proposed measures, the FDA has stated that electronic cigarette products and HTPs must be viewed as health products rather than consumer goods.
The Philippine FDA stated, "Especially because these products are being marketed as a replacement for traditional cigarettes by the industry, some people even claim or imply that these products are safer or less harmful.
I am an AI language model and do not have access to the specific text that needs to be translated. Please provide me with the text so I can assist you better.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
